

TABLE OF CONTENTS

TITLE PAGE.....	i
APPROVAL SHEET	ii
DECLARATION OF AUTHENTICITY	iii
ACKNOWLEDGEMENTS	iv
PREFACE	viii
TABLE OF CONTENTS	ix
LIST OF FIGURES.....	xi
LIST OF TABLES.....	xii
LIST OF APPENCIDES	xiii
LIST OF ABBREVIATION	xiv
ABSTRACT.....	xvi
INTISARI.....	xvii
CHAPTER I INTRODUCTION	1
1.1. Background	1
1.2. Research Questions	6
1.3. Research Objectives	6
1.4. Impact of the Study	6
1.5. Research Boundaries	7
CHAPTER II LITERATURE REVIEW	8
2.1. Lung Cancer Cells.....	8
2.1.1. A549 Lung Cancer Cells	9
2.2. Apoptosis	10
2.2.1. Apoptosis Pathways	12
2.3. Poly (ADP-ribose) Polymerase (PARP).....	13
2.4. Green Tea	16
2.4.1. Epigallocatechin-3-Gallate (EGCG)	18
2.5. Western Blotting.....	19
CHAPTER III RESEARCH METHODOLOGY	21
3.1. Research Design.....	21
3.2. Place and Time of Research	22
3.3. Materials.....	22
3.4. Instruments.....	24
3.5. Research Variable.....	25
3.6. Research Operational Definitions	25
3.7. Research Procedures	26
3.7.1. Cell Culture	26
3.7.2. Cell Experiment.....	27
3.7.3. Cell Morphology Capturing	27

3.7.4. Cell Lyses	28
3.7.5. Protein Quantification	29
3.7.6. Electrophoresis	29
3.7.7. Western Blotting	30
3.7.8. Immunodetection	31
3.7.9. Band Intensity Evaluation	32
3.7.10. Comparative Analysis	33
CHAPTER IV RESULTS AND DISCUSSIONS	35
4.1. Effects of EGCG Dose on Cell Morphology	35
4.2. Effects of EGCG on PARP Expression in A549 Cells	37
4.3. Effects of Lower EGCG Doses and Shorter Incubation Times on PARP Expression	38
4.4. Mechanism of Cell Death Induction by EGCG	40
4.5. EGCG and Normal Cell Response Exploring Selectivity and Toxic Risk	46
4.6. Conversion of Experimental EGCG Doses to Human-Equivalent Consumption	47
4.7. Comparison of Tea Products for Their Effectiveness in Lung Cancer Prevention	48
4.8. Pharmacokinetic Considerations of EGCG for Lung Cancer Prevention	58
4.9. Limitations and Future Research	60
CHAPTER V CONCLUSION AND RECOMMENDATION	63
5.1. Conclusion	63
5.2. Recommendation	63
BIBLIOGRAPHY	65
APPENDIX	75